JAK1 and psoriasis: Brepocitinib (formerly known as PF-06700841) is not a selective TYK2 inhibitor (rather a potent TYK2/JAK1 inhibitor), has shown good efficacy in phase II trials in psoriasis with few minor adverse effects, except thrombocytopenia and decreased reticulocyte count (60).